Compare LSE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | WHWK |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.7M | 95.2M |
| IPO Year | 2024 | N/A |
| Metric | LSE | WHWK |
|---|---|---|
| Price | $4.88 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 6.6K | ★ 141.9K |
| Earning Date | 09-30-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $57,385,142.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.03 | $1.39 |
| 52 Week High | $14.99 | $3.81 |
| Indicator | LSE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 61.76 |
| Support Level | $4.03 | $2.36 |
| Resistance Level | $4.95 | $2.85 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 58.73 | 76.47 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment; oil and gas engineering technical services; new energy production and operation; and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment which supplies various equipments, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.